FDA Registers Sinopharm’s COVID-19 Vaccine

BANGKOK, May 28 (TNA) – The Food and Drug Administration today registered the COVILO (BIBP) vaccine developed by Sinopharm. FDA secretary-general Dr Paisarn Dunkum said FDA approved the registration of the COVID-19 vaccine of Sinopharm as the fifth COVID-19 vaccine for emergency use in Thailand. Bio Genetech Co is its importer. COVILO is an inactivated vaccine produced by Beijing Institute of Biological Product Co. A recipient will receive two jabs that are 28 days apart. The World Health Organization already approved the emergency use of the vaccine. (TNA)